Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
46 studies found for:    vedolizumab
Show Display Options
Rank Status Study
1 Withdrawn Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Interventions: Drug: Vedolizumab intravenous injection;   Drug: Vedolizumab subcutaneous injection
2 Recruiting Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
Conditions: Colitis, Ulcerative;   Crohn Disease
Intervention: Drug: Vedolizumab
3 Completed Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
Condition: Healthy
Interventions: Drug: Vedolizumab SC;   Drug: Vedolizumab IV
4 Completed
Has Results
Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Vedolizumab;   Drug: Placebo
5 Not yet recruiting Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
Condition: ULCERATIVE COLITIS
Interventions: Drug: VEDOLIZUMAB;   Drug: ADALIMUMAB
6 Recruiting Phase 4 Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Condition: Colitis, Ulcerative
Interventions: Drug: Vedolizumab;   Drug: Ciprofloxacin;   Drug: Vedolizumab Placebo
7 Recruiting Dose Finding Study of Vedolizumab for Graft-Versus-Host Disease (GvHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Condition: Allogeneic Hematopoietic Stem Cell Transplantation
Intervention: Drug: Vedolizumab
8 Recruiting Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Vedolizumab;   Drug: Placebo
9 Completed
Has Results
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: vedolizumab
10 Recruiting Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo
11 Active, not recruiting Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo
12 Not yet recruiting Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Condition: Crohn Disease
Intervention: Drug: Vedolizumab
13 Not yet recruiting Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
Conditions: Colitis, Ulcerative;   Crohn Disease
Intervention: Drug: Vedolizumab
14 Not yet recruiting Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
Conditions: Crohn's Disease;   Ulcerative Colitis;   Inflammatory Bowel Disease
Intervention: Drug: Vedolizumab
15 Completed
Has Results
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
Condition: Inflammatory Bowel Disease
Interventions: Drug: Vedolizumab;   Drug: Placebo;   Biological: Hepatitis B vaccine;   Biological: Oral cholera vaccine
16 Recruiting Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis
Condition: Colitis, Ulcerative
Interventions: Drug: Vedolizumab IV 300 mg;   Drug: Placebo IV;   Drug: Vedolizumab SC 108 mg;   Drug: Placebo SC
17 Completed
Has Results
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: vedolizumab;   Other: Placebo
18 Completed
Has Results
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: vedolizumab;   Other: Placebo
19 Recruiting An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
Condition: Colitis, Ulcerative
Interventions: Drug: Vedolizumab;   Drug: Adalimumab placebo;   Drug: Adalimumab;   Drug: Vedolizumab placebo
20 Completed
Has Results
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years